Immunome (NASDAQ:IMNM – Get Free Report) and Lucy Scientific Discovery (NASDAQ:LSDI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst recommendations and institutional ownership.
Risk & Volatility
Immunome has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Comparatively, Lucy Scientific Discovery has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Immunome and Lucy Scientific Discovery, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immunome | 0 | 0 | 6 | 0 | 3.00 |
| Lucy Scientific Discovery | 0 | 0 | 0 | 0 | N/A |
Earnings & Valuation
This table compares Immunome and Lucy Scientific Discovery’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immunome | $10.78 million | 85.92 | -$106.81 million | ($7.55) | -2.05 |
| Lucy Scientific Discovery | $16,732.00 | 2.11 | -$8.99 million | ($7.00) | 0.00 |
Lucy Scientific Discovery has lower revenue, but higher earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Lucy Scientific Discovery, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Immunome and Lucy Scientific Discovery’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immunome | -1,829.44% | -37.33% | -26.06% |
| Lucy Scientific Discovery | N/A | -294.74% | -137.65% |
Institutional and Insider Ownership
44.6% of Immunome shares are owned by institutional investors. Comparatively, 72.6% of Lucy Scientific Discovery shares are owned by institutional investors. 8.6% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Immunome beats Lucy Scientific Discovery on 8 of the 13 factors compared between the two stocks.
About Immunome
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
About Lucy Scientific Discovery
Lucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada.
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
